Posted by Michael Wonder on 28 Nov 2018
Bayer receives EU approval for its haemophilia A treatment Jivi
27 November 2018 - The safety and efficacy profile of Jivi has been demonstrated in more than five years of clinical studies.
Bayer announced today that Jivi (BAY94-9027) has been approved by the European Commission for the treatment and prophylaxis of bleeding in previously treated patients 12 years of age or older with haemophilia A. The recommended prophylactic regimen for Jivi is every five days or, based on patient clinical characteristics, can also be every 7 days or twice weekly.
The approval is based on results from the PROTECT VIII trial.
